Featured News

For the first time ever, the NIH has released a Notice of Special Interest to provide dedicated research funding for the study of celiac disease.

I am pleased to share a research grant awarded to the Dubcovsky Lab at UC Davis for Development of a Novel Dietary Treatment for Celiac Disease that may significantly reduce the suffering experienced by our patient community.

Thanks to your support, we have been remarkably successful in advancing our shared mission over the past year. What follows are some highlights of some of our most important accomplishments.

On November 13 and 14, more than 2,000 supporters moved 3.1 miles to raise funds and awareness for celiac disease at the 2021 Turkey Trot. Thank you to all the participants, sponsors, and donors who made this event a success. 

EpiLynx by Dr. Liia is pleased to announce its continued sponsorship of the Celiac Disease Foundation, a national nonprofit organization dedicated to accelerating diagnosis, treatments, and a cure for celiac disease through research, education, and advocacy.

Registration for the CDF Virtual Turkey Trot ends tomorrow! This is your last chance to join us for a weekend of accelerating celiac disease research and community fun. Register now!

Now, you can earn a Certificate of Training in Treating Gluten-Related Disorders from the Academy of Nutrition and Dietetics and receive grant reimbursement sponsored by Proud Sponsor Schär. Learn more and get free product from Schär with your reimbursement!

Adhering to a strict gluten-free diet requires diligence and regular check-ins to determine whether new food sources may contain gluten. Check out CDF Proud Sponsor Gluten Detect’s at-home test kit to monitor gluten-free diet compliance and ensure you’re sticking to it!

We are proud to announce that the Celiac Disease Foundation has received a 100 Overall Score from Charity Navigator.

We are pleased to share the video recording of Dr. Jocelyn Silvester discussing what you need to know about pediatric celiac disease now and in the future.